Clabel (clarithromycin) coated tablets 500 mg. №14


Manufacturer: Turkey



Treatment of infections caused by clarithromycin-sensitive microorganisms:

Infections of the upper respiratory tract, i.e. the nasopharynx (tonsillitis, pharyngitis), and infections of the paranasal sinuses.
Infections of the lower respiratory tract (bronchitis, acute lobar pneumonia and primary atypical pneumonia).
Skin and soft tissue infections (impetigo, folliculitis, erysipeloid, furunculosis, infected wounds).
Acute and chronic odontogenic infections.
Disseminated or localized mycobacterial infections caused by Mycobacterium avium or Mycobacterium intracellulare. Localized infections caused by Mycobacterium chelonae, Mycobacterium fortuitum, or Mycobacterium kansasi.
H. pylori eradication in patients with duodenal ulcer with inhibition of hydrochloric acid secretion (clarithromycin activity against H. pylori at neutral pH is higher than at acidic pH)